# US 11,442,057 B2 · Method for screening anticancer agent inhibiting binding of AIMP2-DX2 and HSP70 > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,442,057 B2 - Document ID: US11442057B2 - Status: Granted - Kind: B2 - Application number: 16/125,113 - Filed: 2018-09-07 - Published: 2019-01-31 - Granted: 2022-09-13 - Earliest claimed: 2016-03-07 - Assignees: Medicinal Bioconvergence Research Center - Applicants: Medicinal Bioconvergence Research Center - Inventors: Sunghoon Kim; Dae Gyu Kim; Semi Lim - Web page: https://patentgrep.com/patent/US11442057B2 ## CPC - G01N 33/5011: {for testing antineoplastic activity} - A61K 31/404: Indoles, e.g. pindolol - A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol - A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links - A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy - G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q) - G01N 33/575: for cancer - G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention relates to a method for screening an anticancer agent which inhibits the binding of AIMP2-DX2 and HSP70. In addition, the pharmaceutical composition for preventing or treating cancer comprising, as an active ingredient, an anticancer agent screened according to the method of the present invention inhibits the expression of HSP70 or inhibits the binding of HSP70 and AIMP2-DX2, thereby lowering the level of AIMP2-DX2 protein, and can effectively prevent the progression of cancer. As such, the pharmaceutical composition can be useful for developing a cancer treating agent. ## Claims ### Claim 1 A method for screening an anti-cancer agent, the method comprising the steps of: (a) contacting AIMP2-DX2 or a fragment thereof with HSP70 or a fragment thereof in the presence or absence of a test substance; (b) measuring a binding level of AIMP2-DX2 or a fragment thereof with HSP70 or a fragment thereof in the presence or absence of the test substance; (c) comparing the binding level of AIMP2-DX2 or a fragment thereof with HSP70 or a fragment thereof in the presence of the test substance with the binding level of AIMP2-DX2 or a fragment thereof with HSP70 or a fragment thereof in the absence of the test substance to determine a change in the binding level of AIMP2-DX2 or a fragment thereof with HSP70 or a fragment thereof by the test substance; (d) selecting the test substance that reduces the binding level of AIMP2-DX2 or a fragment thereof with HSP70 or a fragment thereof; and (e) verifying an anti-cancer activity of the selected test substance in cells or animals, wherein the cancer is a cancer expressing AIMP2-DX2, wherein AIMP2-DX2 comprises the amino acid sequence of SEQ ID NO: 1 and the fragment of AIMP2-DX2 comprises amino acid residues 1 to 87 of SEQ ID NO: 1, wherein the fragment of AIMP2-DX2 has a binding affinity to HSP70, and wherein HSP70 comprises the amino acid sequence of SEQ ID NO: 3, and the fragment of HSP70 consists of amino acid residues 385 to 536 of SEQ ID NO: 3, wherein the fragment of HSP70 has a binding affinity to AIMP2-DX2. ### Claim 2 (depends on 1) The method of claim 1, wherein the method further comprises the following steps between the steps (d) and (e); (1) contacting the test substance with a cell expressing AIMP2-DX2; (2) measuring a protein level of AIMP2-DX2 in the cell and in a control cell with which the test substance is not contacted, respectively; and (3) selecting the test substance which reduces the protein level of AIMP2-DX2 in comparison with the control cell. ### Claim 3 (depends on 1) The method of claim 1, wherein the binding level in step (b) is measured by at least a method selected from the group consisting of a two-hybrid method, a co-immunoprecipitation assay, a co-localization assay, a scintillation proximity assay (SPA), an UV or chemical cross-linking method, mass spectrometry (MS), nuclear magnetic resonance (NMR), a fluorescence polarization assay (FPA) and an in vitro pull-down assay. ### Claim 4 (depends on 1) The method of claim 1, wherein the cancer is selected from the group consisting of breast cancer, lung cancer, colon cancer, anal cancer, astrocytoma, leukemia, lymphoma, head and neck cancer, liver cancer, testicular cancer, cervical cancer, sarcoma, hemangioma, esophageal cancer, eye cancer, larynx cancer, oral cancer, mesothelioma, myeloma, oral cavity cancer, rectal cancer, laryngopharyngeal cancer, bladder cancer, uterine cancer, ovarian cancer, prostate cancer, cancer of the large intestine, pancreatic cancer, kidney cancer, stomach cancer, skin cancer, basal cell carcinoma, melanoma, squamous cell carcinoma, oral squamous cell carcinoma, colorectal cancer, glioblastoma, endometrial cancer and malignant glioma. ### Claim 5 (depends on 1) The method of claim 1, wherein the anti-cancer agent is selected from the group consisting of siRNA, shRNA, miRNA, ribozyme, DNAzyme, peptide nucleic acid (PNA), antisense oligonucleotide, antibody, aptamer, peptide, natural extracts and chemical substance.